Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
PROMETEO II is a single-arm window of opportunity trial to evaluate biologic and
anti-proliferative effects of palbociclib and letrozole in HR+/HER2-negative operable breast
cancer (BC) patients with residual disease after neoadjuvant chemotherapy (NAC) and help to
identify biomarkers for better patient selection.